Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023

Published: November 2017
No. of Pages: 132
Price: Single User: US $ 4950  US $ 3960 Corporate User: US $ 14850  US $ 8910
    ReportsandReports

This report is available at 20% Discount for Single User License and 40% Discount for Corporate Users License till 31 December 2017. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight’s “Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology
and Market Forecast-2023” Report provides an overview of the disease and global market
trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United
States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE)
and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment
practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to
2023 segmented by seven major markets. In addition, the report provides the historical and
forecasted of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer
indications till 2023.
The report covers the number of patients for 10 cancer indications (i.e., Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin’s disease and Non-Hodgkin Lymphoma), who are at risk of developing
CIN as an adverse event of the chemotherapies of respective cancers.
Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for
chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was
later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute
to majority of the market size, of CIN. However, New Chemical Entities are expected to launch
in the near future. According to DelveInsight, the worldwide CIN market is estimated to
increase at a CAGR of 3.37% for the forecast period i.e., 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Published By: Delve Insight
Product Code: Delve Insight128


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: